News Four more drugs in keenly watched ALS trial miss the mark ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.
News UK pharma has concerns about the new NHS 10-year plan The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face